Realty Income Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Realty Income Corp trades at $65.09 (market cap $60.60B), while State Street SPDR S&P Biotech ETF trades at $152.12. The key difference: Realty Income Corp pays a 5% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| O | XBI | |
|---|---|---|
Market Cap | $60.60B | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $67.56 | $164.28 |
52-Week Low | $55.93 | $85.16 |
Enterprise Value | $90.40B | — |
Dividend Yield | 5% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Trailing returns across standard periods
Latest headlines on both assets
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →